Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment

Trial Profile

An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Abivertinib-maleate (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Hangzhou ACEA Pharmaceutical Research
  • Most Recent Events

    • 31 Jan 2019 Status changed from recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 28 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top